Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study

Modern Rheumatology

Volumn 24, Issue 5, 2014, Pages 734-743

  Tanaka, Yoshiya ^a   Yamamoto, Kazuhiko ^b   Takeuchi, Tsutomu ^c   Yamanaka, Hisashi ^d   Ishiguro, Naoki ^e   Eguchi, Katsumi ^f   Watanabe, Akira ^g   Origasa, Hideki ^h   Shoji, Toshiharu ⁱ   Miyasaka, Nobuyuki ^j   Koike, Takao ^k  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^e NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f Sasebo Shiritsu Sogo Hospital   (Japan)

^g TOHOKU UNIVERSITY   (Japan)

^h UNIVERSITY OF TOYAMA   (Japan)

ⁱ Department of Clinical Research and Development UCB ^*  (Japan)

^j TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^k NTT CORPORATION   (Japan)

more..

Author keywords

Certolizumab pegol; Clinical study; Rheumatoid arthritis; TNF inhibitor; TNF

Indexed keywords

CERTOLIZUMAB PEGOL; METHOTREXATE; PLACEBO; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BREAST CANCER; BRONCHITIS; COLON CANCER; CONTUSION; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECZEMA; FEMALE; HUMAN; HYPERTENSION; JAPANESE (PEOPLE); LIVER FAILURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; SUBARACHNOID HEMORRHAGE; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; ARTHRITIS, RHEUMATOID; ARTHROGRAPHY; CONTROLLED STUDY; DISEASE COURSE; DRUG ADMINISTRATION; JAPAN; MIDDLE AGED; QUALITY OF LIFE; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; RETREATMENT; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ARTHROGRAPHY; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; JAPAN; MALE; METHOTREXATE; MIDDLE AGED; POLYETHYLENE GLYCOLS; QUALITY OF LIFE; RETREATMENT; TREATMENT OUTCOME;

EID: 84906318255     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2014.881709     Document Type: Article

References (25)

1. Balanescu A, Wiland P. Maximizing early treatment with biologics in patients with rheumatoid arthritis: The ultimate breakthrough in joints preservation. Rheumatol Int. 2013; 33(6): 1379-86.
2. Sharma P, Pathak K. Are biological targets the fi nal goal for rheumatoid arthritis therapy?. Expert Opin Biol Ther. 2012;12(12):1611-22.
3. Moreland L.W, Schiff M.H, Baumgartner S.W, Tindall E.A, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999;130(6):478-86.
4. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, afully human anti-Tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum. 2003;48(1):35-45.
5. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infl iximab and methotrexate. Arthritis Rheum. 2004;50(4):1051-65.
6. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. Arthritis Rheum. 2002;46:1443-50.
7. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-Tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebocontrolled, 52-week trial. Arthritis Rheum. 2004;50(5):1400-11.
8. Tanaka Y. Recent progress in the treatment of rheumatoid arthritis. Clin Calcium 2012;22(2):169-78.
9. Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, et al. Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-Tumor necrosis factor alpha agents. Infl amm Bowel Dis. 2007;13(11):1323-32.
10. Horton S, Walsh C, Emery P. Certolizumab pegol for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2012; 12(2): 235-49.
11. Keystone E, Heijde D, Mason D Jr, Landew e.R, Vollenhoven RV, Combe B, et al. Certolizumab pegol plus methotrexate is signifi cantly more eff ective than placebo plus methotrexate in active rheumatoid arthritis: Fi ndings of a fi fty-Two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 2008;58(11):3319-29.
12. Smolen J, Landewe RB, Mease P, Brzezicki J, Mason D, Luijtens K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: The RAPID2 study. A randomised controlled trial. Ann Rheum Dis. 2009;68(6):797-804.
13. Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: The J-RAPID randomized, placebo-controlled trial. Mod Rheumatol. 2013;(epub ahead of print) doi:10.3109/14397595.2013.864224
14. Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, et al. Efficacy and safety of certolizumab pegol without methotrexate coadministration in Japanese patients with active rheumatoid arthritis: The HIKARI randomized, placebo-controlled trial. Mod Rheumatol. 2013;(epub ahead of print) doi:10.3109/14397595.2013.843764
15. Keystone E.C, Combe B, Smolen J, Strand V, Goel N, Van Vollenhoven R, et al. Sustained Efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID1 trial. Rheumatology (Oxford) 2012; 51(9): 1628-38.
16. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classifi cation of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-24.
17. Ramiro S, Van Tubergen AM, Landewe RB. RAPID and FAST4WARD trials: Certolizumab pegol for rheumatoid arthritis. Expert Rev Clin Immunol. 2010;6(5):713-20.
18. Strand V, Mease P, Burmester GR, Nika i.E, Coteur G, Van Vollenhoven R, et al. Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: Results from the RAPID1 randomized controlled trial. Arthritis Res Ther. 2009;11(6):R170.
19. Connock M, Tubeuf S, Malottki K, Uthman A, Round J, Bayliss S, et al. Certolizumab pegol (CIMZIA) for the treatment of rheumatoid arthritis. Health Technol Assess. 2010;14(Suppl 2):1-10.
20. Boers M for the COBRA Study Group. Demonstration of response in rheumatoid arthritis patients who are nonresponders according to the American College of Rheumatology 20% criteria: The paradox of benefi cial treatment eff ects in nonresponders in the ATTRACT trial. Arthritis Rheum. 2001;44(11):2703-4.
21. Keystone E, Landewe R, Van Vollenhoven R, Combe B, Strand V, Mease P, et al. Long-Term safety and Efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension. Ann Rheum Dis. 2013;(epub ahead of print
22. Patel A.M, Moreland L W. Certolizumab pegol: A new biologic targeting rheumatoid arthritis. Expert Rev Clin Immunol. 2010; 6(6): 855-66.
23. Kaushik V.V, Moots R J. CDP-870 (certolizumab) in rheumatoid arthritis. Expert Opin Biol Ther. 2005;5(4):601-6.
24. Shankar S, Handa R. Biological agents in rheumatoid arthritis. J Postgrad Med. 2004;50(4):293-9.
25. Benedek T G. Methotrexate: From its introduction to non-oncologic therapeutics to anti-TNF-Alpha. Clin Exp Rheumatol. 2010;28 (5 Suppl 61):S3-8.